▸ In the near term, we will be continuing to focus on assembling a regulatory package and submitting an NDA. These activities will provide clarity on the additional capital needed for the program.· · · ● ● 2 rw ▸ The ongoing trade tensions resulting from tariff discussions/impositions can materially and adversely impact our business.· · · ● ● 2 ▸ There are risks and uncertainties associated with our recently acquired ALXN1840 program which could result in delays in development or in gaining marketing approval, if at all, and such delays will negatively impact our financial condition.· · · ● ● 2 ▸ We also maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.· · · ● ● 2 ▸ Perceptions of these challenges and risks in the market may adversely impact our stock price and our ability to successfully raise funding as we focus our preclinical and clinical efforts on our radiopharmaceutical program.· · ● ● ● 3 ▸ Radiopharmaceuticals are a relatively novel approach to cancer imaging and treatment, which may create significant and potentially unpredictable challenges for them.· · ● ● ● 3 rw ▸ Market variables, such as inflation of product costs, labor rates and fuel, freight and energy costs, tariffs, as well as geopolitical events could likely cause us to suffer significant increases in our operating and administrative expenses.· ● ● ● ● 4 rw ▸ We have a limited operating history.· ● ● ● ● 4 ▸ We may need to raise additional funding or find one or more suitable pharmaceutical partners to continue to advance our clinical programs; finance our regulatory, pre-commercial and commercial activities; and support our preclinical studies.· ● ● ● ● 4 rw ▸ If the interim analysis for our ongoing Validive Phase 2b/3 clinical program yields a no-go decision, our business would be adversely impacted.· ● · · · 1 ▸ We rely on a limited number of contracted manufacturing plants.If we need to enlist new contract manufacturers, it will delay our MNPR-101 radiopharmaceutical program and our camsirubicin program and may increase the costs of our clinical trials.· ● ● · · 2 rw ▸ As a recently established entity, we have a limited operating history.● · · · · 1 ▸ Existing and new investors will experience dilution as a result of future sales or issuances of our common stock and future option exercises under our 2016 Stock Incentive Plan and any amendments to the plan.● ● ● · · 3 ▸ Holders of the shares of our common stock will have no control of our operations or of decisions on major transactions.● ● ● ● · 4 ▸ Our failure to meet the other continued listing requirements of The Nasdaq Capital Market could result in a de-listing of our common stock.● ● ● · · 3 rw ▸ Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.● · · · · 1 ▸ We rely on a limited number of contracted manufacturing plants.● · · · · 1 ▸ Even if we complete the clinical trials we discussed with the FDA or TGA, there is no guarantee that at the time of submission the FDA or TGA will accept our NDA or BLA based on the trials discussed.● ● · ● ● 4 rw ▸ Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us difficult, limit attempts by our stockholders to replace or remove our current management or Board and adversely affect our stock price.● ● ● ● ● 5 ▸ Any of these factors could harm our ongoing international clinical operations and supply chain, as well as any future international expansion and operations and, consequently, our business, financial condition, prospects and results of operations.● ● ● ● ● 5 ▸ Any success we may achieve at a given stage of our clinical trials does not guarantee that we will achieve success at any subsequent stage, including without limitation final FDA or other regulatory organizations’ approval.● ● ● ● ● 5 ▸ As a company, we have never completed a clinical trial and have limited experience in completing regulatory filings and any delays in regulatory filings could materially affect our financial condition.● ● ● ● ● 5 ▸ Changes to the patent law in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.● ● ● ● ● 5 ▸ Commercial success of our product candidates will depend on the acceptance of these products by physicians, payers and patients.● ● ● ● ● 5 rw ▸ Competition and technological change may make our product candidates less competitive or obsolete.● ● ● ● ● 5 ▸ Corporate, non-profit, and academic collaborators may take actions (including lack of effective actions) to delay, prevent, or undermine the success of our products.● ● ● ● ● 5 ▸ Data provided by collaborators and other parties upon which we rely have not been independently verified and could turn out to be inaccurate, misleading, or incomplete.● ● ● ● ● 5 ▸ Delaware law and provisions in our amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the potential trading price of our common stock.● ● ● ● ● 5 ▸ Effective collaboration with the FDAfor the approval of drug candidates is a highly demanding process which can result in increased time and expense to gain approvals.● ● ● ● ● 5 rw ▸ Even if we are able to commercialize any drug candidate, such drug candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.● ● ● ● ● 5 ▸ Foreign currency exchange rates may adversely affect our consolidated financial statements.● ● ● ● ● 5 ▸ Future legislation or executive or private sector actions may increase the difficulty and cost for us to commercialize our products and adversely affect the prices obtained for such products.● ● ● ● ● 5 ▸ Future tax reform measures may negatively impact our financial position.● ● ● ● ● 5 ▸ If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.● ● ● ● ● 5 ▸ If serious adverse or undesirable side effects are identified during the development of our product candidates, we may abandon or limit our development or commercialization of such product candidates.● ● ● ● ● 5 ▸ If the market opportunities for our current and potential future drug candidates are smaller than we believe they are, our ability to generate product revenues will be adversely affected and our business may suffer.● ● ● ● ● 5 ▸ If we and our third-party licensors do not obtain and preserve protection for our respective intellectual property rights, our competitors may be able to take advantage of our (and our licensors’) development efforts to develop competing drugs.● ● ● ● ● 5 ▸ If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.● ● ● ● ● 5 ▸ If we experience delays or difficulties in the enrollment of subjects to our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented, which could materially affect our financial condition.● ● ● ● ● 5 ▸ In certain cases, we may need to rely on a single supplier for a particular manufacturing material or service, and any interruption in or termination of service by such supplier could delay or disrupt the commercialization of our products.● ● ● ● ● 5 ▸ Intellectual property disputes could require us to spend time and money to address such disputes and could limit our intellectual property rights.● ● ● ● ● 5 ▸ It is uncertain whether product liability insurance will be adequate to address product liability claims, or that insurance against such claims will be affordable or available on acceptable terms in the future.● ● ● ● ● 5 ▸ Negotiated prices for our products covered by a Part D prescription drug plan and other government programs will be lower than the prices we might otherwise obtain.● ● ● ● ● 5 ▸ Our ability to use our net operating loss (“NOL”) carryforwards and certain other tax attributes may be limited.● ● ● ● ● 5 rw ▸ Our present and potential future international operations may expose us to business, political, operational, and financial risks associated with doing business outside of the U.S.● ● ● ● ● 5 ▸ Our products may not be accepted for reimbursement or adequately reimbursed by third-party payers.● ● ● ● ● 5 ▸ Politically divided governmental actions and related political actions outside of government can impact the FDA’s role in the timely and effective review of new pharmaceutical products in the U.S. and our business may be adversely impacted.● ● ● ● ● 5 ▸ group Risks Associated with our Common Stock● ● ● ● ● 5 ▸ group Risks Related to Clinical Development and Regulatory Approval● ● ● ● ● 5 ▸ group Risks Related to Commercialization of Our Product Candidates● ● ● ● ● 5 ▸ group Risks Related to Our Business Operations and Industry● ● ● ● ● 5 ▸ group Risks Related to Our Financial Condition and Capital Requirements● ● ● ● ● 5 ▸ group Risks Related to Our Intellectual Property● ● ● ● ● 5 ▸ group Risks Related to Our Reliance on Third Parties● ● ● ● ● 5 ▸ The financial and operational projections that we may make from time to time are subject to inherent risks.● ● ● ● ● 5 ▸ The patent protection we obtain and preserve for our product candidates may not be sufficient to provide us with any material competitive advantage.● ● ● ● ● 5 ▸ The stock price of our common stock may be volatile or may decline regardless of our operating performance.● ● ● ● ● 5 ▸ The termination of third-party licenses could adversely affect our rights to important compounds or technologies.● ● ● ● ● 5 ▸ There can be no assurance that we will ever provide liquidity to our investors through a sale of our Company.● ● ● ● ● 5 ▸ Unstable market and economic conditions may have serious adverse consequences on our ability to raise funds, which may cause us to delay, restructure or cease our operations.● ● ● ● ● 5 ▸ We are a smaller reporting company and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.● ● ● ● ● 5 rw ▸ We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations, and non-compliance with such laws can subject us to criminal or civil liability and harm our business.● ● ● ● ● 5 rw ▸ We do not intend to pay dividends for the foreseeable future and, as a result, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.● ● ● ● ● 5 ▸ We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.● ● ● ● ● 5 ▸ We have a limited operating history, expect to incur significant operating losses, and have a high risk of never being profitable.● ● ● ● ● 5 ▸ We have limited the liability of and indemnified our directors and officers.● ● ● ● ● 5 ▸ We may become involved in securities class action litigation that could divert management’s attention and harm our business.● ● ● ● ● 5 ▸ We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.● ● ● ● ● 5 ▸ We may not be able to enforce our intellectual property rights throughout the world.● ● ● ● ● 5 ▸ We, or any future collaborators, may not be able to obtain and maintain orphan drug exclusivity for our product candidates in the U.S. and Europe.● ● ● ● ● 5 
